Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

9,640JPY
9:51am IST
Change (% chg)

¥-120 (-1.23%)
Prev Close
¥9,760
Open
¥9,759
Day's High
¥9,812
Day's Low
¥9,637
Volume
387,100
Avg. Vol
1,404,832
52-wk High
¥11,490
52-wk Low
¥5,402

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.67
Market Cap(Mil.): ¥2,849,415.00
Shares Outstanding(Mil.): 296.57
Dividend: 70.00
Yield (%): 1.56

Financials

  4523.T Industry Sector
P/E (TTM): 50.65 28.28 30.39
EPS (TTM): 189.68 -- --
ROI: 7.58 12.94 12.61
ROE: 9.28 14.96 14.80

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

18 Aug 2018

CORRECTED-(OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

* Wholesale price before discount is $16,970 for a 30-day supply

18 Aug 2018

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

17 Aug 2018

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

26 Jul 2018

Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | Video

07 Jul 2018

BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

* Says it forms business and capital alliance with Eisai Co Ltd

28 Mar 2018

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

23 Mar 2018

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

09 Mar 2018

CORRECTED-UPDATE 3-Eisai clinches Merck deal to develop and sell cancer drug, shares soar

* Eisai's drug Lenvima already approved in dozens of countries

09 Mar 2018

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima

* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)

08 Mar 2018

Earnings vs. Estimates